Clinical Trials
7 trialsNCT03842228 2026-05-29
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04317105 2026-05-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03517956 2022-07-14
ROCOCO
Bayer
Phase 1 Completed
NCT05010096 2022-05-27
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01411410 2017-10-11
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT00962611 2017-10-06
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT01392521 2015-04-17
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Bayer
Phase 1 Completed